research PA13: A Hair’s Breadth from Misdiagnosis
A 15-year-old boy was correctly diagnosed with a rare skin condition after initially being misdiagnosed.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Characterization of Scalp, Eyelash, and Eyebrow Hair Regrowth in Patients with Severe Alopecia Areata Randomized to Placebo in BRAVE AA1 and BRAVE AA2 Trials
Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
research Comparison of Efficacy of Autologous Platelet Rich Plasma Therapy With 5% Topical Minoxidil Spray in Treating Alopecia Areata: A Head-to-Head Assessment of Novel Approaches
Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.
research Role of Platelet-Rich Plasma Therapy in the Treatment of Alopecia Areata and Atrophic Acne Scars
PRP therapy effectively treats alopecia areata and atrophic acne scars.
research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Baricitinib Maintains Regrowth of Hair, Eyebrows, and Eyelashes Over 3 Years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Alopecia Areata Treated with Homeopathic Preparation of Phosphorus: Two Evidence-Based Case Reports
Phosphorus homeopathy treatment led to complete hair regrowth in two Alopecia Areata patients.
research Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
research Multi-Ancestry Tandem Repeat Association Study of Hair Color Using Exome-Wide Sequencing
Tandem repeats significantly influence hair color, especially darker shades, across different ancestries.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Is Thyroid Dysfunction a Common Cause of Telogen Effluvium? A Retrospective Study
Hypothyroidism is often linked to the hair loss condition telogen effluvium.
research Growth Factors and Microneedling in Alopecia Areata: A Narrative Review
Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
research Hairy Tongue Associated With the Use of Baricitinib Therapy for Ophiasis Pattern Alopecia Areata
A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
research Study of the Effect of Topical Mometasone with Intralesional Platelet-Rich Plasma Versus Topical Mometasone Alone in the Treatment of Alopecia Areata
Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.
research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research A Chance Finding of High Grade Prostate Cancer in a 35-Year-Old Male – A Case Report and Outcomes of Robotic Radical Prostatectomy in Young Men with Prostate Cancer
A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
research Upadacitinib for the Treatment of Alopecia Areata – A Case Report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Distribution of SALT Scores by Therapeutic Response in Patients with Severe Alopecia After 52 Weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Two-Dimensional Planimetry for Alopecia Areata Severity Evaluation Compared With Severity of Alopecia Tool: A Pilot Study
Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.
research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.